Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-20-062797

Chief Executive Officer sold 55,000 shares at an average $68.73 ($3,780,347)

  • Chief Executive Officer acquired 55,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Anzalone Christopher Richard Chief Executive Officer 2020-12-08 Option exercise +16,324 $2.01 $32,811 2,521,561 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-08 Sale −16,324 $67.97 $1,109,542 2,505,237 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Option exercise +38,676 $2.01 $77,739 2,543,913 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Sale −16,726 $67.27 $1,125,158 2,527,187 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Sale −12,067 $69.80 $842,277 2,515,120 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Sale −5,880 $70.87 $416,716 2,509,240 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Sale −4,003 $71.61 $286,655 2,505,237 D
Derivatives
Anzalone Christopher Richard Chief Executive Officer 2020-12-08 Option exercise · Stock Option (right to buy) −16,324 879,219 D
Anzalone Christopher Richard Chief Executive Officer 2020-12-09 Option exercise · Stock Option (right to buy) −38,676 840,543 D
Open-market sales · 55,000 sh · avg $68.73 · $3,780,347
Loading xslF345X03/doc4.xml…